Key result
MYH7 gene mutations in Chinese patients with hypertrophic cardiomyopathy were associated with a higher risk of sudden death (13.5% vs 0%, p<0.001) and shorter life span compared to MYBPC3 mutations.
Why the study?
Do MYH7 gene mutations confer a worse prognosis compared to MYBPC3 mutations in Chinese patients with hypertrophic cardiomyopathy?
Cohort (n=116)
Do MYH7 gene mutations confer a worse prognosis compared to MYBPC3 mutations in Chinese patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 13.5% vs 0%
p-value: p=< 0.001
In Chinese patients with hypertrophic cardiomyopathy, MYH7 mutations (especially in the global region) are associated with a more malignant clinical phenotype and worse prognosis than MYBPC3 mutations.
No takes yet. Share an insight, caveat, or question.
May heighten sudden death vigilance in MYH7-positive Chinese HCM patients; extends genotype-phenotype data but leaves practice change open.
Hui et al. (2008) conducted a cohort in Hypertrophic Cardiomyopathy (n=116). MYH7 gene mutations vs. MYBPC3 gene mutations was evaluated on sudden death risk (p=< 0.001). MYH7 gene mutations in Chinese patients with hypertrophic cardiomyopathy were associated with a higher risk of sudden death (13.5% vs 0%, p<0.001) and shorter life span compared to MYBPC3 mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: